MM1.S

MM1.S、MM.1S、MM1.S细胞、MM.1S细胞、MM1.S人lambda骨髓瘤细胞

Cell line name MM1.S

Synonyms MM.1S; MM1-S; MM-1S; MM1S

Accession CVCL_8792

Resource Identification Initiative To cite this cell line use: MM1.S (RRID:CVCL_8792)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Population: African American.

Characteristics: Produces IgA lambda (ATCC=CRL-2974).

Characteristics: Sensitive to dexamethasone.

Doubling time: 80 hours (PubMed=25984343); ~72 hours (ATCC=CRL-2974).

Microsatellite instability: Instable (MSI-low) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: B-cell; CL=CL_0000236.

PubMed=12691914; DOI=10.1016/S0301-472X(03)00023-7

Greenstein S., Krett N.L., Kurosawa Y., Ma C.-G., Chauhan D., Hideshima T., Anderson K.C., Rosen S.T.

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Exp. Hematol. 31:271-282(2003)

 

PubMed=14760100; DOI=10.1158/1078-0432.CCR-0793-03

Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., Munshi N.C.

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.

Clin. Cancer Res. 10:770-776(2004)

 

PubMed=16956823

Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.

The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.

Haematologica 91:1234-1240(2006)

 

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698

Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P.R., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Cancer Cell 12:131-144(2007)

 

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

Characterization of MYC translocations in multiple myeloma cell lines.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

 

PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235

Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Haematologica 96:574-582(2011)